BAKER BROS. ADVISORS LP other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

52 4.00%

of those in investment advisory functions:

18 28.57%

Registration:

SEC, Approved, 3/5/2012

AUM:

21,976,239,930 -5.09%

of that, discretionary:

21,976,239,930 -5.09%

GAV:

21,976,239,930 -5.09%

Avg Account Size:

10,988,119,965 -5.09%

SMA’s:

YES

Private Funds:

2

Contact Info

212 xxxxxxx

Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
36B 31B 26B 20B 15B 10B 5B
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Infinity Pharmaceuticals Inc.
04/05/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

DBV Technologies S.A. ADR
04/05/2021

Mr. Michael J. Goller is an Independent Non-Executive Director at BeiGene Ltd. and a Partner at Baker Bros. Advisors LP. He is on the Board of Directors at DBV Technologies SA and BeiGene Ltd ...

Market Watch

BioCryst Pharmaceuticals Inc.
04/01/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Is ACADIA Pharmaceuticals (ACAD) Stock A Buy or Sell?
03/29/2021

there exists a few notable hedge fund managers who were boosting their holdings considerably (or already accumulated large positions). Story continues The largest stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was held by Baker Bros. Advisors ...

Yahoo Finance

Is ACADIA Pharmaceuticals (ACAD) Stock A Buy or Sell?
03/29/2021

there exists a few notable hedge fund managers who were boosting their holdings considerably (or already accumulated large positions). The largest stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was held by Baker Bros. Advisors, which reported holding $ ...

Insider Monkey

Mereo BioPharma: An Overlooked Bio Company
03/25/2021

I anticipate their Cash is currently around ~$190M USD, which I expect is enough to easily fund their efforts until ... purchases that have taken place. Baker Bros owns just over 39M shares ...

Seeking Alpha


Private Funds Structure

Fund Type Count GAV
Hedge Fund 2 $21,976,239,930

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
FRANKLIN TEMPLETON INVESTMENT MANAGEMENT LIMITED 151.0m - - - - - - 151.0m 25.3b 2
OPPENHEIMER & CO. INC. 13.9m - - - - - - 13.9m 27.5b 1
D.A. DAVIDSON & CO. 58.0m - - - - - - 58.0m 27.9b 1
EAGLE CAPITAL MANAGEMENT LLC 172.5m - - - - - - 172.5m 29.1b 1
CAXTON ASSOCIATES LP 25.6b - - - - - - 25.6b 25.6b 6
D. E. SHAW INVESTMENT MANAGEMENT, L.L.C. 13.0b - - - - - - 13.0b 22.1b 15
PARALLAX VOLATILITY ADVISERS, L.P. 8.1b - - - - - - 8.1b 8.1b 1
DIAMOND HILL CAPITAL MANAGEMENT INC 20.8m - - - - - - 20.8m 27.4b 1
TOWERS WATSON INVESTMENT MANAGEMENT LIMITED 6.1b - - - - - - 6.1b 23.5b 3
POLAR CAPITAL LLP 17.7b - - - - - - 17.7b 25.1b 24

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
45337C102 Incyte Corporation $2,271,687,070 26.00% 9.00% 0.00%
07725L102 BeiGene, Ltd. $1,906,206,263 22.00% -9.00% -9.00%
004225108 ACADIA Pharmaceuticals Inc. $1,342,091,002 15.00% 50.00% 0.00%
558868105 Madrigal Pharmaceuticals, Inc. $455,771,861 5.00% 102.00% 27.00%
76243J105 Rhythm Pharmaceuticals, Inc. $294,132,839 3.00% 91.00% -5.00%
60468T105 Mirati Therapeutics, Inc. $242,134,600 3.00% 294.00% 192.00%
501575104 Kymera Therapeutics, Inc. $152,656,327 2.00% 131.00% 26.00%
76155X100 Revolution Medicines, Inc. $147,663,483 2.00% 98.00% 91.00%
45258D105 Immunocore Holdings plc $172,216,342 2.00% 32.00% 0.00%
00288U106 AbCellera Biologics Inc. $130,814,690 1.00% 37.00% 10.00%

Brochure Summary

Overview

A. BBA, a Delaware limited partnership, is an investment adviser located in New York, New York and has been providing investment advisory services since January 2000. BBA serves as a discretionary investment adviser to certain private investment funds (each, a “Fund” or “Client” and collectively, the “Funds” or “Clients”), which are generally organized as limited partnerships. BBA’s founders and principal owners are Julian Baker and Felix Baker (the “Managing Members”). B. BBA generally has broad investment authority with respect to its Clients, subject to certain pre-agreed limitations applying on a portfolio-wide basis with respect to certain Clients and set forth in the applicable Client’s constituent documents (the “Investment Limits”). BBA’s Clients invest in public and private securities and related assets and revenue streams of life sciences and health care companies and cash management investments. These securities include, but are not limited to: (1) equity securities, including exchange-listed and over-the- counter securities; (2) warrants; (3) corporate debt securities, including convertible bonds; (4) options contracts on securities; (5) ETFs; and (6) money market funds. BBA focuses on public securities, but, from time to time, also recommends and makes investments on behalf of its Clients in private companies, life sciences and related health care intellectual property, royalty streams and other “non-public” investment opportunities. BBA provides
investment advice with respect to other investment securities and instruments as is consistent with each respective Client’s investment objective. C. BBA neither tailors its advisory services to the needs of individual investors in the Funds (“Investors”) nor accepts Investor-imposed investment restrictions other than the Investment Limits (which apply to all Investors in an applicable Fund). Though BBA utilizes a similar strategy for all of the Funds, it may tailor the advisory services it provides to Clients to the extent that certain investments cannot be held by certain of BBA’s Clients for legal, tax, portfolio concentration, or other investment based reasons. BBA has, however, in the past established, and may in the future establish additional, managed accounts or single investor funds for large or strategic investors. The advisory agreements for such managed accounts or funds will generally be subject to different terms than the Funds, including but not limited to, liquidity, investment objectives, guidelines and restrictions, fees and other terms. Only Baker Brothers Life Sciences, L.P., and its feeder Fund HCIF Offshore LP, are currently open to new Investors. D. BBA does not participate in wrap fee programs. E. As of January 1, 2023, the amount of Client assets managed by BBA (“RAUM”) was $23,154,517,129, all of which is managed by BBA on a discretionary basis. BBA does not currently manage any Client assets on a non-discretionary basis.